iCANsee is harnessing nanotechnology to pioneer the ocular delivery of cannabinoids.

Nanotech offers a scientific path to improved eye health.

Nanotechnology is the foundation of an effective delivery platform for ocular medications set to revolutionize eye care.

iCANsee was recently awarded a NOFAR grant by the Israeli Innovation Authority;
the grant, totaling NIS 440,000 (US$125,000), will support the company’s nanoformulation development.

Human eyes have a high density of cannabinoid receptors making them receptive to cannabis treatments.

Current ocular treatment options are inefficient, with few patients finding relief. These options include:

• Ocular Steroids
• Artificial Tears
• NSAIDs (Nonsterodial Anti Inflammatory Drugs)

iCANsee is the first-mover in incorporating cannabis into ocular health. Our distinguished scientific advisory board ensures the clinical validity of iCANsee ocular cannabis products, testing the quality and efficacy of each formulation prior to market.

Medical cannabis WILL impact ocular medicine, and iCANsee is leading the way.

I'd like an update on iCANsee and other new medical cannabis companies in the iCAN Incubator.

iCANsee offers a range of products for common eye conditions


ICS-P3 Nanotechnology enabled cannabioid delivery formulation designed to penetrate the eye treating uveitis, ocular pain, macular degeneration, glaucoma


ICS-H1 Hemp extract Formulation that stimulates natural lubrication, reduces inflammation, decreases discomfort.
ICS-CX Cannabis Extract (including THC) for recreational & therapeutic use


Our findings for THC suggest that a dual CB1/GPR18 agonist may prove advantageous. The study of phytocannabinoids such as THC and CBD, but also others derived from the plant, may therefore point to novel strategies to promote ocular health.

Δ9-Tetrahydrocannabinol, an active ingredient of the plant cannabis sativa, is an agonist of the cannabinoid receptors CB1 and CB2 that could potentially be such a dual-acting, antiglaucoma agent. The presence of cannabinoid receptors in the ocular tissues have been recently confirmed,which supports the concept that a localized IOP-reducing mechanism, rather than the central nervous system, is involved.

We subsequently tested the efficacy of our formulation in whole-eye experiments by loading the nanoparticles with cannabigerolic acid (CBGA). Our formulation exhibits over a 300% increase in transcorneal penetration over control formulations. This work paves the way for the introduction of novel products targeting ocular diseases to the market.


For all media inquirues, please contact Laura Kam at Laura@kamgs.com

Close Menu